Memantine Hydrochloride Capsule, Extended Release
FDA Label NDC 70771-1321

The following Structured Product Label (SPL) was submitted to the FDA by Zydus Lifesciences Limited for the product Memantine Hydrochloride (NDC 70771-1321). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package Label.Principal Display Panel

Memantine Hydrochloride Extended-release Capsules, 7 mg

NDC 70771-1321-3

30 Counts

Memantine Hydrochloride Extended-release Capsules, 7 mg (D1f0893c 420d 4045 B773 B402760464c1 06)

Memantine Hydrochloride Extended-release Capsules, 14 mg

70771-1322-3

30 Counts

Memantine Hydrochloride Extended-release Capsules, 14 mg (D1f0893c 420d 4045 B773 B402760464c1 07)

Memantine Hydrochloride Extended-release Capsules, 21 mg

NDC 70771-1323-3

30 Counts

Memantine Hydrochloride Extended-release Capsules, 21 mg (D1f0893c 420d 4045 B773 B402760464c1 08)

Memantine Hydrochloride Extended-release Capsules, 28 mg

NDC 70771-1324-3

30 Counts

Memantine Hydrochloride Extended-release Capsules, 28 mg (D1f0893c 420d 4045 B773 B402760464c1 09)

* Please review the disclaimer below.